Mutations of p53 decrease sensitivity to the anthracycline treatments in bladder cancer cells.

In conclusion, our results demonstrated that the anthracycline-induced resistance in bladder cancer cells positively correlated with TP53 mutations in the tetramerization domain in J82 and TCCSUP cells. Further, AD 312 and AD 198 are promising chemotherapeutic drugs for bladder cancer, especially in combination with PRIMA-1. PMID: 29983877 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Related Links:

Conclusions: Our results suggest thatNOS3 895G#x3e;T andCBR3 730G#x3e;A are genetic markers that can be used to predict tumor recurrence in NMIBC patients receiving intravesical instillations of THP. The effects of those 2 SNPs are independent of the EORTC scores. Further studies with larger sample sizes and longer follow-ups are needed to confirm our results.Chemotherapy 2018;63:191 –197
Source: Chemotherapy - Category: Cancer & Oncology Source Type: research
AbstractPurpose of ReviewEndoscopy coupled with targeted resections represents a cornerstone in the diagnosis, staging, and treatment of patients with bladder cancer. Direct visualization can be challenging and imprecise due to patient-, tumor-, and surgeon-specific factors. We will review contemporary endoscopic technologies and techniques used to improve our ability to safely identify and resect malignant lesions in patients with bladder cancer.Recent FindingsEnhanced endoscopic imaging technology may improve detection rates for bladder cancer throughout the upper and lower urinary tract, which may lead to improvements i...
Source: Current Urology Reports - Category: Urology & Nephrology Source Type: research
A meta-analysis identified several factors that are correlated with locoregional recurrence in patients with nonmetastatic muscle-invasive bladder cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
Conclusion: Our results suggest that USC markers are linked with poor prognosis of NMIBC patients, especially in patients with tumors in the trigone and posterior wall.Cell Physiol Biochem 2018;48:2364 –2373
Source: Cellular Physiology and Biochemistry - Category: Cytology Source Type: research
Authors: Gao F, Wang X, Chen S, Xu T, Wang X, Shen Y, Dong F, Zhong S, Shen Z Abstract Poor response and chemotherapy resistance to cisplatin (DDP)‑based therapy frequently lead to treatment failure in advanced bladder cancer; however the underlying mechanism is extremely complex and unclear. Furthermore, cancerous inhibitor of protein phosphatase 2A (CIP2A), a recently identified human oncoprotein, has been shown to play important regulatory roles in cancer cell survival. The present study aimed to investigate the correlation of CIP2A with sensitivity to DDP in bladder cancer cells. In the present study, knockdo...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
We present a revised mathematical model of the immune response to Bacillus Calmette-Guérin (BCG) treatment of bladder cancer, optimized according to biological and clinical data accumulated during the last decade. The improved model accounts for cytotoxic T lymphocyte differentiation as an integral element of the delayed immune response, as well as the logistic growth terms for cancer cell proliferation. Three equilibria are demonstrated for the proposed model, which is assumed to be influenced by white noise stochastic perturbations that are directly proportional to the system state deviation from an equilibrium. S...
Source: Computational and Mathematical Methods in Medicine - Category: Statistics Tags: Comput Math Methods Med Source Type: research
ConclusionsTaken together, our findings indicate that miR-129-5p and Wnt5a may be novel therapeutic targets for overcoming gemcitabine resistance in bladder cancer treatment.
Source: International Urology and Nephrology - Category: Urology & Nephrology Source Type: research
AbstractPurposeThe purpose of the study was to retrospectively determine whether there are metastases to the chest in patients with primary non-muscle-invasive urothelial carcinoma in the bladder on the follow-up computed tomography (CT).MethodsWe analyzed 328 patients with follow-up chest CT for urothelial carcinoma of the bladder diagnosed between January 2004 and September 2013. We divided patients into four groups: Ta (n = 74), T1 (n = 78), carcinoma in situ (CIS,n = 25), and ≥ T2 (n = 151). We used the chest CT to determine whether there were positive f...
Source: International Urology and Nephrology - Category: Urology & Nephrology Source Type: research
Conditions:   Prostate Cancer;   Benign Prostatic Hypertrophy;   Bladder Stones;   Kidney Stones Intervention:   Diagnostic Test: NV-VPAC1 PCa Urine Diagnostic Test Sponsors:   Intermountain Health Care, Inc.;   NuView Diagnostics Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: September 2018Source: European Urology, Volume 74, Issue 3Author(s): Oscar Rodríguez Faba, Alberto Breda, Joan Palou
Source: European Urology - Category: Urology & Nephrology Source Type: research
More News: Bladder Cancer | Cancer | Cancer & Oncology | Cardiology | Heart | Study